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Introduction: Zika virus infection (ZIKV) has emerged as a significant threat for the health of pregnant 
women and newborns in populations living or visiting Latin America since the epidemic begun in 2015. 
Reported possible consequences included particularly the risk of associated microcephaly, still to be 
proved in detail and confirmed, but potentially of other congenital defects. Methods: The method used 
a database journals in PubMed, ProQuest and Medline used the keywords, after the data obtained was 
reviewed journal research was conducted. Search result found 22 journal but in accordanced with the 
topic was 8 journal with a span of February-March 2016. Result: 1). Provide further support for a link 
between maternal ZIKV infection and fetal and placental abnormalities that is not unlike that of other 
viruses that are known to cause congenital infections characterized by intrauterine growth restriction 
and placental insufficiency. 2). women with a positive ZIKV RT-PCR or with cocerning findings on 
USS should be referred to a fetal medicine service for evaluation and follow up. 3). Although there are 
several barriers for developing vaccines and other measures for pregnant women, these barriers are 
surmountable with concerted efforts and leadership. Discussion: 1). Women with suspected or 
confirmed ZIKV infection should be monitored closely, with serial ultrasonography to evaluate for signs 
of placental insufficiency, given the risks of fetal death and intrauterine growth restriction. 2). All 
pregnant women who have potentially ben exposed to ZIKV should be revered to their local maternity 
unit for 4-weekly fetal ultrasound scan (USS) examinations. 3). No specific antiviral treatment is 
available for zika virus disease.  
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INTRODUCTION  
Pregnancy is a physiologically dynamic 
state. The immune profile of a pregnant woman 
is responsive to the changing levels of sex 
hormones and evolves through the course of 
pregnancy. However, most of the current 
knowledge base for vaccine response is derived 
from observational studies conducted in the 
latter part of pregnancy, with limited data 
available from the first and early second 
trimester or from randomized clinical trials. On 
the other hand, clinical, practical, and public 
health considerations require that vaccine use 
not be restricted to women with advanced 
gestational age. Given that a substantial portion 
of Zika’s teratogenic effects may occur in the 
earlier phase of pregnancy, administration of 
any forthcoming Zika vaccine will be most 
beneficial prior to or during the early parts of 
pregnancy. The knowledge gap for early 
pregnancy vaccine responses and safety will 
make the task of developing and recommending 
an effective Zika vaccine for use across 
pregnancy challenging. Infection with Zika 
virus in pregnancy is associated with arange off 
etalabnormalities, including fetal death and 
growth  restriction in addition to neonatal 
microcephaly. 
The current epidemic of ZIKV 
infection began in early 2015 in northeastern 
Brazil. Since then ZIKV transmission has been 
confirmed in 35 countries.4 One theory is that 
ZIKV was carried to Brazil by infected Pacific 
Islanders visiting an international canoeing 
event in Rio de Janeiro in August 2014. In 
September 2015 clinicians working in 
Pernambuco state noticed an increase in 
newborn babies with microcephaly. The 
Ministry of Health quickly established a register 
and within 3 months recorded 4180 suspected 
cases, including 68 deaths, compared to a total 
of 147 reports in the whole of 2014.5 A review 
of the first 35 cases noted that 74% of mothers 
reported a rash during pregnancy and 71% of 
infants had severe microcephaly.6 ZIKV RNA 
was detected in the amniotic fluid of two 
mothers and from the brain of a baby who died 
shortly after birth.7 Taken together these data 
indicate a strong association between ZIKV 
infection during pregnancy and microcephaly, 
although a causal relationship is yet to be 
proven. ZIKV infection has an incubation 
period of 3–12 days. Patients may present with 
a fever, rash, arthralgia, and conjunctivitis. The 
illness is self-limiting and lasts for up to a week. 
Severe cases are uncommon.  
It can be difficult to distinguish ZIKV 
infection from other viral illnesses such as 
dengue and chikungunya, which are also 
transmitted by Aedes mosquitoes. Population 
seroprevalence studies from the outbreak in 
Micronesia showed that 80% of ZIKV 
infections were asymptomatic,8 which presents 
a diagnostic problem in pregnancy if ZIKV 
crosses the placenta. 
 
METHODOLOGY 
The method used a database journals in 
PubMed, ProQuest and Medline used the 
keywords, after the data obtained was reviewed 
journal research was conducted. Search result 
found 22 journal but in accordanced with the 
topic was 8 journal with a span of February-
March 2016. Keywords used were zika virus 
and pregnant. Fulltext articles and abstracts 
were reviewed to choose studies that fit the 
criteria. Criteria for inclusion in this review was 
zika virus and pregnant women. Keyword 
search using the above get 22 article, but the 
article in accordance with article 8 inclusion 
criteria. The article was  used as a further 
samples are identified and presented in table 1. 
DISCUSSION 
Zika virus is a flavivirus transmitted by 
Aedes (Stegomyia) species of mosquitoes. In 
May 2015, the World Health Organization 
confirmed the first local transmission of Zika 
virus in the Americas in Brazil. The virus has 
spread rapidly to other countries in the 
Americas; as of January 29, 2016, local 
transmission has been detected in at least 22 
countries or territories, including the 
Commonwealth of Puerto Rico and the U.S. 
Virgin Islands. Zika virus can infect pregnant 
women in all three trimesters. Although 
pregnant women do not appear to be more 
susceptible to or more severely affected by Zika 
virus infection, maternal–fetal transmission has 
been documented. Several pieces of evidence 
suggest that maternal Zika virus infection is 
associated with adverse neonatal outcomes, 
most notably microcephaly. Because of the 
number of countries and territories with local 
Zika virus transmission, it is likely that obstetric 
health care providers will care for pregnant 
women who live in or have traveled to an area 
of local Zika virus transmission. We review 
information on Zika virus, its clinical 
presentation, modes of transmission, laboratory 
testing, effects during pregnancy, and methods 
of prevention to assist obstetric health care 
providers in caring for pregnant women 
considering travel or with a history of travel to 
areas with ongoing Zika virus transmission and 
pregnant women residing in areas with ongoing 
Zika virus transmission. 
Although the most common mode of 
transmission of Zika virus to humans is from the 
bite of an infected mosquito, other modes of 
transmission have been documented, including 
maternal–fetal transmission. Transmission 
through blood transfusion and laboratory 
exposure also have been reported. Three cases 
of probable sexual transmission of Zika virus 
have been reported. The length of time that Zika 
virus remains in semen is unknown. Zika virus 
RNA has been identified in breast milk, but 
attempts to culture the virus were unsuccessful. 
Transmission through organ or tissue 
transplantation is theoretically possible, but has 
not been documented. Zika virus testing can be 
performed to detect the presence of viral RNA, 
antigen, or antibodies. Reverse transcription-
polymerase chain reaction (RT-PCR) has been 
validated, and its performance has been 
evaluated in individuals with symptoms 
consistent with Zika virus disease. Reverse 
transcription-polymerase chain reaction testing 
to detect Zika virus RNA can be performed on 
serum, amniotic fluid, and other fluids, as well 
as tissues. Reverse transcription-polymerase 
chain reaction testing of serum is recommended 
within approximately 1 week of symptom onset. 
Viral clearance can occur within 7 days of 
symptom onset; thus, a negative RT-PCR result 
on a test performed 5–7 days after symptom 
onset may not exclude Zika virus infection. 
Immunohistochemical staining also can be used 
to detect Zika virus antigen in tissues, including 
within placental tissues. Serologic testing can 
detect immunoglobulin M (IgM) by enzyme-
linked immunosorbent assay as early as 4 days 
after illness onset19; however, a negative result 
on serum collected less than 7 days after illness 
onset does not exclude Zika virus disease. In 
addition, a positive IgM result can be difficult 
to interpret; cross-reaction due to previous 
flavivirus exposure, including vaccination (eg, 
yellow fever vaccine) and infections (eg, 
dengue virus), can occur. Zika virus IgM levels 
may be elevated as a result of this cross-
reaction. Plaque-reduction neutralization 
testing can be performed to measure virus-
specific neutralizing antibodies to Zika virus 
and other flaviviruses. 
The levels of neutralizing antibodies 
can be compared between flaviviruses, but these 
tests may be difficult to interpret in individuals 
previously infected or vaccinated against 
flaviviruses. Health care providers are 
encouraged to work with their health 
departments to facilitate interpretation of Zika 
virus tests. As of February 12, 2016, 
commercial tests for Zika virus are not 
available. Zika virus IgM and plaque-reduction 
neutralization testing is performed only at CDC 
and a limited number of state and local health 
departments. Health care providers should 
contact their state or territorial health 
department for assistance with arranging testing 
and interpreting results. As an arboviral disease, 
Zika virus disease is a nationally notifiable 
condition and laboratory confirmed cases 
should be reported to the state, territorial, or 
local health department. 
Zika virus infection during pregnancy 
and effects on the fetus. Data on pregnant 
women infected with Zika virus are limited. 
Pregnant women can be infected with Zika virus 
in any trimester, and symptoms reported during 
pregnancy are similar to those in nonpregnant 
individuals. No evidence exists to suggest that 
pregnant women are more susceptible to Zika 
virus infection or are more severely affected 
once infected. Maternal–fetal transmission of 
Zika virus has been demonstrated throughout 
pregnancy. The full spectrum of outcomes that 
might be associated with congenital Zika virus 
infection is unknown; however, microcephaly, 
brain atrophy, ventricular enlargement, and 
intracranial calcifications have been reported in 
neonates who have tested positive for Zika virus 
infection. Ocular defects, scalp rugae, and joint 
contractures also have been reported in cases of 
suspected congenital Zika virus infection (ie, 
neonates with microcephaly for whom Zika 
virus testing had not been performed). In 
addition to the association with brain 
abnormalities in neonates, Zika virus RNA has 
been detected in the pathologic tissue 
specimens of fetal losses; however, it is 
unknown whether Zika virus caused the fetal 
loss. 
The frequency of maternal–fetal 
transmission and the risk that a fetus infected 
with Zika virus will develop microcephaly or 
other congenital defects are unknown. It is also 
unknown whether the timing or severity of 
symptoms, viral load, maternal immune 
response, or other factors increase the risk of 




No  Title Author/y
ear 














































No  Title Author/y
ear 










2 Pregnancy in 













































































range of fetal 
abnormalities























































































































No  Title Author/y
ear 






























































No  No  Pregnan
t women 
A further 





and fetal and 
placental 
abnormalitie

















8 Zika virus nd 
pregnancy: A 














































Global  Nursing  Challenges  in  The  Free  Trade  Era 
CONCLUSION AND 
RECOMMENDATION 
Provide further support for a link 
between maternal ZIKV infection and fetal and 
placental abnormalities that is not unlike that of 
other viruses that are known to cause congenital 
infections characterized by intrauterine growth 
restriction and placental insufficiency. Women 
with a positive ZIKV RT-PCR or with 
cocerning findings on USS should be referred 
to a fetal medicine service for evaluation and 
follow up. Although there are several barriers 
for developing vaccines and other measures for 
pregnant women, these barriers are 
surmountable with concerted efforts and 
leadership. All pregnant women who have 
potentially ben exposed to ZIKV should be 
revered to their local maternity unit for 4-
weekly fetal ultrasound scan (USS) 
examinations. To assist health care providers 
who care for pregnant travellers to and residents 
of area zika virus transmission, CDC, has 
develop interim clinical guidance. 
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